Research
Hormonal
Holding one dose of GLP-1 or GIP agonists significantly reduces the risk of clinically significant RGV.
Holding the medication prior to the procedure is advisable to minimize RGV risk.
StrongSupportsmedium confidence
Clinically significant RGV occurred in 3.1% in the hold group vs 25.0% in the continue group.
Why this rating
Based on a randomized clinical trial design.
Source
Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy
Akram I. Ahmad et al. · JAMA Internal Medicine · 2026
rct · n=60Cited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →